S'abonner

A prospective evaluation of lung function at three and six months in patients with previous SARS-COV-2 pneumonia - 21/09/21

Doi : 10.1016/j.rmed.2021.106541 
Nicla Orzes a, 1, Laura Pini a, b, , 1 , Guido Levi a, Silvia Uccelli a, Francesca Cettolo a, Claudio Tantucci a, b
a Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy 
b Respiratory Medicine Unit, Spedali Civili di Brescia, Brescia, Italy 

Corresponding author. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.Department of Clinical and Experimental SciencesUniversity of BresciaBresciaItaly

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Objective

This study investigated the consequences of Coronavirus Disease 2019 (COVID-19) pneumonia on lung function in the first 6 months after hospital discharge.

Methods

A prospective lung function assessment in SARS-CoV2 patients with COVID-19 pneumonia, hospitalized between March and April 2020, was conducted with spirometry measurements including lung volumes, mainly total lung capacity (TLC), lung diffusion capacity for carbon monoxide (DLCO) collected at 3 months after hospital discharge. Patients with restrictive ventilatory defect or impaired DLCO or both were re-evaluated at 6 months with global spirometry and chest HRCT scan.

Results

Among 40 consecutive patients, 19 (48%) had normal pulmonary functional tests (group A), and 21 (52%) showed residual lung function abnormalities at 3 months after hospital discharge (group B). In group B, 4 patients (19%) had only loss of lung volume as shown by TLC reduction (group 1), 13 patients (62%) had decreased both TLC and DLCO (group 2), and 4 patients (19%) had isolated reduction in DLCO (group 3). At 6-month follow-up in group 1, although all patients improved, only one normalized total lung capacity (TLC). In group 2, TLC and DLCO increased significantly (p < 0.01), but only 3 patients reached normal values. In group 3, DLCO improved for most patients, normalizing in 50% of them. At 6-months significant correlations between an internal-built chest HRCT scan severity score and TLC (r2 = 0.33; p < 0.01) and DLCO (r2 = 0.32; p < 0.01) were found.

Conclusions

Nearly 50% of patients recovered in the post-critical phase. Most of those with abnormal pulmonary function tests at 3 months improved subsequently, but only another 29% (6 out of 21) reached normal values at 6 months. These results indicate that lung function spontaneous recovery is faster at first and occurs more slowly thereafter, leaving more than one third (15 out of 40) of patients with abnormal lung function tests at 6 months.

Le texte complet de cet article est disponible en PDF.

Highlights

After COVID-19 pneumonia, nearly 50% of patients fully recovered lung function.
Most of those with abnormal pulmonary function tests at 3 months improved later.
However, only another 29% reached normal values at 6 months.
Lung function recovery is faster at first and occurs more slowly thereafter.
More than one-third of patients keep abnormal lung function tests at 6 months.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, SARS-CoV2, Lung function, Pneumonia, Spirometry


Plan


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 186

Article 106541- septembre 2021 Retour au numéro
Article précédent Article précédent
  • Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease
  • Masato Kono, Koichi Miyashita, Ryutaro Hirama, Yuiko Oshima, Kenichiro Takeda, Yasutaka Mochizuka, Akari Tsutsumi, Hideki Miwa, Yoshihiro Miki, Dai Hashimoto, Takafumi Suda, Hidenori Nakamura
| Article suivant Article suivant
  • Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis
  • Jesus Sancho, Santos Ferrer, Enric Burés, José Luis Díaz, Teresa Torrecilla, Jaime Signes-Costa, Emilio Servera

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.